RASSF1 and cancer: In a validation cohort from the NELSON trial (subsequently diagnosed with cancer vs. control patients), this targeted methylation analysis approach remained specific (99.3%) but sensitivity was very low (17% for RASSF1A, 28% for the panel RASSF1A, 3OST2, and PRDM14) [55].